Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Urovant Sciences Ltd (UROV)

Urovant Sciences Ltd (UROV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 531,746
  • Shares Outstanding, K 32,743
  • Annual Sales, $ 0 K
  • Annual Income, $ -146,750 K
  • 60-Month Beta 2.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade UROV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.14
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/11/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -2.27
  • Number of Estimates 2
  • High Estimate -1.93
  • Low Estimate -2.61
  • Prior Year -1.57
  • Growth Rate Est. (year over year) -44.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.10 +0.84%
on 03/02/21
16.26 -0.12%
on 03/19/21
+0.07 (+0.43%)
since 02/26/21
3-Month
16.03 +1.31%
on 12/30/20
16.26 -0.12%
on 03/19/21
+0.20 (+1.25%)
since 12/24/20
52-Week
7.15 +127.13%
on 11/02/20
16.26 -0.12%
on 03/19/21
+6.09 (+60.00%)
since 03/26/20

Most Recent Stories

More News
Sumitovant Biopharma Completes Acquisition of Urovant Sciences

NEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: UROV) jointly announced today the completion of the merger...

UROV : 16.24 (+0.06%)
Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by...

DASH : 66.23 (-1.08%)
MASS : 14.35 (-6.27%)
ACEV : 10.01 (-0.10%)
ASPL : 9.93 (+0.30%)
ACTC : 18.09 (-4.84%)
PACE : 11.20 (+0.36%)
UBER : 23.35 (+0.47%)
UROV : 16.24 (+0.06%)
NEOS : 1.1500 (-2.54%)
AYTU : 0.5622 (+4.11%)
HTGC : 13.62 (-3.34%)
HCXZ : 25.20 (unch)
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended December 31, 2020.

UROV : 16.24 (+0.06%)
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board

Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product,...

UROV : 16.24 (+0.06%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, NHLD, COHR, UROV; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

MDCA : 5.42 (-3.39%)
NHLD : 3.25 (unch)
COHR : 264.03 (+0.24%)
UROV : 16.24 (+0.06%)
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

UROV : 16.24 (+0.06%)
WTRE : 19.38 (+1.58%)
CBMG : 19.75 (unch)
NAV : 44.50 (+0.16%)
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROV

NEW YORK, Jan. 16, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CBMG : 19.75 (unch)
CGIX : 4.61 (-2.33%)
UROV : 16.24 (+0.06%)
MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CBMG : 19.75 (unch)
ALSK : 3.40 (+0.29%)
UROV : 16.24 (+0.06%)
NAV : 44.50 (+0.16%)
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CBLI, WORK, and UROV

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Lifshitz Law Firm, P.C.: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties...

CBMG : 19.75 (unch)
CBLI : 3.17 (-7.31%)
WORK : 45.20 (+0.09%)
UROV : 16.24 (+0.06%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – UROV, EIGI, SNCA, CLCT

NEW YORK, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

UROV : 16.24 (+0.06%)
EIGI : 9.49 (unch)
SNCA : 9.9600 (-1.19%)
CLCT : 91.92 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international...

See More

Key Turning Points

3rd Resistance Point 16.28
2nd Resistance Point 16.26
1st Resistance Point 16.25
Last Price 16.24
1st Support Level 16.22
2nd Support Level 16.20
3rd Support Level 16.19

See More

52-Week High 16.26
Last Price 16.24
Fibonacci 61.8% 12.78
Fibonacci 50% 11.70
Fibonacci 38.2% 10.63
52-Week Low 7.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar